Search

Search Constraints

You searched for: Author/Creator Iwata, Tomoko

Search Results

2. Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial. (24th July 2022)

5. Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR‐Reduced trial. (21st June 2021)

6. Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction. Issue 14 (13th September 2022)

7. Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR‐Reduced. (24th October 2022)

8. FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation. Issue 3 (19th September 2018)

9. Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice. Issue 2 (31st March 2014)

10. Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced. (9th January 2022)